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Abstract
Objective—To examine prospective changes in cardiovascular disease (CVD) and type-2 diabetes
risk factors in young adult first episode psychotic (FEP) patients treated with second generation
antipsychotic medications.
Methods—At baseline, fasting serum and anthropometric measures were obtained from 45 FEP
patients and 41 healthy adults (controls) of similar age, ethnicity and sex; sixteen of the FEP patients
remained on the same antipsychotic medication and were available for a second blood draw at 24
weeks of treatment. Serum was assayed for glucose, insulin, triglycerides, total cholesterol and high
and low density lipoproteins (HDL, LDL), adiponectin, leptin, interleukin 6, E-selectin and
VCAM-1. Wilcoxon nonparametric tests were used to compare risk markers between the FEP and
control group at baseline and to evaluate pre-post treatment changes within the FEP group.
Results—At baseline, the distributions of risk marker values were similar between the two groups
and the percentages of FEP patients and healthy controls who were overweight/obese, dyslipidemic,
hyperglycemic, and hyperinsulinemic did not differ. At 24 weeks, compared to baseline, FEP patients
showed significant increases in BMI (p=0.0002), glucose (p=0.0449), insulin (p=0.0161), cholesterol
(p=0.0129), leptin (p=0.0215), and E-selectin (p=0.0195), and a decrease in adiponectin (p=0.0371).
Conclusions—Among patients with first episode psychosis, 6-month treatment with second
generation antipsychotics is associated with the exacerbation of pre-existing and emergence of new
CVD and diabetes risk factors.
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Compared to the general population, people with schizophrenia have increased risks of
developing cardiovascular disease (CVD) and type 2 diabetes (T2DM) (Brown et al., 2000;
Ryan and Thakore, 2002; Susce et al., 2005), and their life expectancy is shorter by 15 years
primarily because of coronary heart disease (Hennekens et al., 2005). Two important factors
contributing to this increased morbidity and mortality are inherent susceptibility and
antipsychotic medication side effects.
A link between metabolic abnormalities (i.e., high blood glucose and abnormal glucose
tolerance) and psychotic illness was recognized in the pre-antipsychotic era (reviewed by
Kohen, 2004). Some (Ryan et al., 2003) but not all (Arranz et al., 2004, Zhang et al., 2004a)
more recent studies have confirmed this finding. Reasons for elevated glucose parameters in
psychotic illness may include unhealthy lifestyle (Zhang et al., 2004a; McEvoy and Brown,
1999; Ryan et al., 2004) in the early stages of schizophrenia as well as genetic factors: diabetes
occurs in up to 30% of the relatives of those with schizophrenia (Mukherjee et al., 1989).
An association between antipsychotic medication use and metabolic dysregulation has also
been suspected for many years, based on a series of published case reports describing increased
rates of diabetes (Charatan and Bartlett, 1995; Hiles, 1956; Dynes, 1969) in patients taking
chlorpromazine, and on inpatient studies showing that the rate of diabetes in female psychiatric
inpatients rose from roughly 4% to 17% between 1956 and 1968, as antipsychotic use increased
(Thonnard-Neumann, 1968). In the last decade it has become very clear that many second-
generation antipsychotic (SGA) medications also have the propensity to cause significant
weight gain in very short amounts of time and to adversely affect glucose metabolism.
Clozapine and olanzapine have consistently been identified as having the greatest weight gain
liability, followed by risperidone and quetiapine with intermediate weight gain, and then
ziprasidone, haldol, molindone, and aripiprazole with minimal weight gain on average (Allison
et al., 1999b; Christensen et al., 2006; Lieberman et al., 2005l; Marder et al., 2003; Wirshing
et al., 1999). Consistent with their high weight gain profile, clozapine and olanzapine are also
thought to be the two medications most likely associated with glucose dysregulation (reviewed
in Jin et al., 2004).
Individuals with chronic schizophrenia have high rates of overweight and obesity (Susce et al.,
2005; Homel et al., 2002), but it is not known whether they are heavier than the general adult
population. One analysis, based on 1989 National Health Interview Survey data (i.e., from the
pre-SGA era), found similar BMI distribution for men with and without schizophrenia, but that
women with schizophrenia had a statistically and clinically significantly higher mean BMI
compared to women without this illness (Allison et al., 1999a). In the same paper, comparison
of BMI from a large group of schizophrenia clinical trial subjects with BMI data from the
National Health and Nutrition Examination Survey III showed similar albeit non-significant
trends. However, the results of these analyses may have been biased because some patients
with very low or very high BMI, as well as those with significant medical illness, were
excluded. Efforts to study this phenomenon in patients who are drug naïve or early in treatment
compared to age- and sex-matched controls have been limited and yielded mixed results: some
(Thakore et al., 2002) but not all (Ryan et al., 2004; Zhang et al., 2004a) studies found higher
BMI in patients, and some (Ryan et al., 2004; Thakore et al., 2002) but not all (Zhang et al.,
2004a) studies found higher intra-abdominal fat (IAF) in patients.
The finding of higher IAF in SGA-treated patients is of interest because of the association
between abdominal obesity and higher levels of the proinflammatory adipokines (leptin,
interleukin 6 [IL-6], C-reactive protein, and tumor necrosis factor) and less secretion of the
protective adipokine, adiponectin. These proinflammatory agents are thought to induce
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oxidative stress thereby exacerbating underlying pathological processes leading to
dyslipidemia, glucose intolerance, insulin resistance, and endothelial dysfunction that are
common in obesity and type II diabetes mellitus (T2DM) (Sonnenberg et al., 2004). Previous
cross-sectional studies found both higher (Togo et al., 2004) and lower (Richards et al.,
2006) adiponectin levels in patients treated with olanzapine compared to healthy controls as
well as lower levels in untreated patients compared to controls (Cohn et al., 2006). One
additional study found no change in adiponectin after 4 weeks of olanzapine treatment
(Hosojima et al., 2006). Similarly, IL-6 levels were elevated in patients with schizophrenia
compared to controls but appeared unchanged after 12 weeks of risperidone treatment (Zhang
et al., 2004b). Our study extends this work by prospectively evaluating changes in adiponectin,
IL-6, and other important risk markers in patients early in treatment who received SGAs for a
longer duration (approximately six months).
Here, we investigated laboratory cardiovascular disease (CVD) and T2DM risk markers in first
episode psychosis patients who are either antipsychotic naïve or have had only short exposure
to antipsychotics. Sixteen of the patients remained on the same antipsychotic medication for
6 months, and so a second assessment of risk markers was completed in this subgroup. The
markers under investigation include fasting glucose, insulin, and lipid panel, as well as novel
risk markers including leptin, adiponectin, and IL-6, and the cellular adhesion molecules
associated with T2DM risk, E-selectin and VCAM-1. These same markers were assayed in a
comparison group of physically and mentally healthy subjects of similar age, ethnicity, gender
and BMI for baseline comparison.
2. Experimental/Materials and methods
2.1. Subjects
Between June 2001 and April 2005, blood from 45 patients experiencing a first episode of
psychosis (FEP) and from 41 healthy control subjects was drawn, processed, and frozen for
later use. Patients were recruited from inpatient wards and outpatient clinics of The University
of North Carolina at Chapel Hill Hospitals or Dorothea Dix State Psychiatric Hospital in
Raleigh, North Carolina. Fifteen of the 45 recruited patients were antipsychotic naïve at the
time of first blood draw, while 12 had less then 2 weeks exposure, eight had 2 to 4 weeks
exposure, and 10 had between 4 and 16 weeks exposure to antipsychotic medication. Seven
patients were inpatients at the time of baseline evaluation. Of those patients already on
medication at baseline assessment, 18 were on risperidone, eight were on olanzapine, one was
on quetiapine, one was on a combination of olanzapine and quetiapine, and two were on
aripiprazole. The FEP subjects were not on any other medication known to effect weight
(lithium, depakote, mirtazepine, stimulants, or weight loss medications). Healthy control
subjects were recruited through advertisements posted on bulletin boards in Chapel Hill and
Durham, North Carolina. Healthy subjects were screened by both a clinical social worker and
a psychiatrist and could have no known psychiatric or medical illness, and were between the
ages of 16 and 40. Healthy subjects were not matched to the patient population. All subjects
consented to having blood drawn and stored as approved by the UNC Investigational Review
Board. Approximately 6 months after the initiation of antipsychotic medication treatment,
blood from 16 of the patient subjects was again drawn, processed, frozen and stored for later
use. Reasons for subject dropout between baseline and follow up were change in antipsychotic
medication (n=13), patient stopped antipsychotic against medical advice (n=11), relocation
(n=3), patient lost to follow-up (n=1) and patient unwilling to have blood drawn (n=1). Sample
size for individual assays ranged from 10 to 14 however, due to research personnel error, or
insufficient quantity of blood drawn to run all assays. The median time to follow-up was 174
days. Of these 16 patients, none of whom switched antipsychotic medications during the study
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period: nine were on risperidone, four were on olanzapine, two were on quetiapine, and one
was on aripiprazole.
2.2. General Methods
Height was measured using a wall mounted stadiometer. Weight was measured on a digital
scale that was calibrated monthly with subjects wearing one layer of light clothing and no
shoes. BMI was calculated by weight in kg/height (in meters2) for all subjects where both
height and weight were available (41 FEP subjects and 34 controls).
Subjects were requested both orally and with written notice of the need to fast for at least 10
hours before bloodwork. Additionally, subjects were called the day before scheduled blood
draw as a reminder to fast overnight. On the morning of the bloodwork, subjects were asked
if they had anything to eat or drink for the previous 10 hours. If they had anything other than
water and their medication, bloodwork was rescheduled. Blood was collected in BD vacutainer
SST tubes and then spun for 10 min (25° C, 3000 rpm); the serum was stored at −80° C. Fasting
levels for glucose, cholesterol (total), HDL and triglycerides were all processed on the VITROS
5,1 FS Chemistry platform (OrthoClinical Diagnostics) in McLendon Clinical Laboratory at
UNC Hospital on serum specimens. Low-density lipoprotein (LDL) cholesterol was estimated
using the calculation: LDL = total cholesterol – [HDL – (triglycerides/5)] (Friedewald et al.,
1972). Blood for these tests was assayed on the day of the blood draw. The Clinical Nutrition
Research Center of UNC Chapel Hill performed the enzyme-linked immunosorbent assays for
sE-Selectin, sVCAM-1, IL-6, leptin, adiponectin, (R&D Systems, Inc.) and insulin (Linco
Research) as directed by the manufacturers, in a single batch. The Qualitative Insulin
Sensitivity Check Index (QUICKI) method was used to estimate insulin sensitivity (Katz et
al., 2000).
2.3. Statistical Methods
The Fisher’s Exact Test was used to compare ethnicity distributions between patient and control
groups. Chi-square Test was used to compare gender distributions between patient and control
groups The Mean Score Test was used to compare the BMI categorical distributions between
patient and control groups. Due to small sample sizes and non-normal distributions for some
of the variables, nonparametric tests were used to compare risk markers between groups
(Wilcoxon Rank Sum Test) at baseline as well as to evaluate pre-post treatment changes in
each risk marker within the patient group (Wilcoxon Signed Rank Test and Sign Test).
Associations between BMI and lab values were evaluated using Spearman Rank Correlations.
Computations were performed using SAS software (v. 9.1, SAS Institute, Cary, NC), and a p-
value less than 0.05 was considered statistically significant. Given the exploratory nature of
this study, p-values were not adjusted for the multiple testing and should be viewed with
appropriate caution.
3. Results
3.1. Subject Characteristics at Baseline
3.1.1 Comparison of Patient Group to Healthy Control Group—Mean patient age
was 23.33 year (SD 6.07) and mean healthy control age was 25.39 (SD 5.55), giving a
borderline significant p value of p=0.0530. Thirty-three percent of the patient group were
female compared to 46 % of the control group (p = 0.2178). 82.22 % of the patients were
Caucasian, while 15.56 were African American and 2.22 % were Asian. This was not
statistically different from the Healthy Control Group (70.7% Caucasian, 29.3% African
American and no Asians). Mean BMI was also not significantly different. (Table 1).
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3.1.2 Comparison of Longitudinal Group of Patients to Patients with only
Baseline Data—Sixteen of the 45 patient subjects remained on the same medication and
were available to have a second blood draw. There were no significant differences between
the group followed longitudinally and those with only baseline measurement with respect to
ethnicity (p =0.8017), gender distribution (p=0.3312), range of BMI (p=0.6303) and the
percentage who were drug free at baseline (p=0.7463).
3.1.3 Baseline comparison of Drug Naïve Patients to Patients on Medication—
Fifteen patient subjects were drug naïve at baseline and 30 were taking an antipsychotic
medication. Of those taking medication, 12 had less then 2 weeks exposure, eight had 2 to 4
weeks exposure, and 10 had between 4 and 16 weeks exposure to antipsychotic medication.
There were no significant differences between these groups with respect to ethnicity (p
=0.3583), gender distribution (p=0.7384), or range of BMI (p=0.4593). Additionally, there
were no significant differences in any of the lab values.
3.2. Risk Markers at Baseline
3.2.1 Comparison of Patient Group to Healthy Control Group—At baseline, many
FEP subjects already displayed several of the usual risk factors for CVD and diabetes, but did
not differ substantially in these respects from the healthy controls: overweight or obese: patients
= 41.9%, controls = 52.9% (p > 0.36); elevated cholesterol: patients = 28.6%, controls = 25.0%
(p > 0.80); elevated triglycerides: patients = 16.7%, controls = 13.9% (p > 0.76); elevated LDL:
patients = 21.4%, controls = 22.2% (p > 0.99); low HDL: patients = 19.0%, controls = 2.8%
(p > 0.03); elevated insulin: patients = 9.3%, controls = 4.9% (p > 0.67); elevated glucose:
patients = 2.5%, controls = 0.0% (p > 0.99). As displayed in Table 2, the distributions of
demographic characteristics and risk markers did not differ between patients and controls at
baseline with the exception of glucose: the median and interquartile range for glucose were
higher in patients than controls (p < 0.05).
3.2.2 Comparison of Longitudinal Group of Patients to Patients with only
Baseline Data—There were no significant differences in baseline risk marker results other
then fasting glucose, which was significantly lower in the group of 16 followed longitudinally
(82.6 +− 11.31) compared to the group (n=29) with only the one timepoint (86.81 +−5.41)
(p=0.0207). This difference becomes non-significant if we consider multiple comparisons.
Numerically this is a small difference and both means are well within the normal range for
glucose.
3.3 Change in Risk Markers at 6 Month Follow-up in Patients
BMI significantly increased with treatment by a median of 3.45 kg/m2 (P = 0.0002). The mean
(SD) BMI changed from 23.93 (4.4) to 27.63 (5.04) kg/m2, and 71.4% of patients were
overweight/obese (up from 41.9% at baseline) (Figure 1). The 6-month changes in all other
risk markers among patients are presented in Table 3. Fasting glucose (P=0.0449) and fasting
insulin (P = 0.0161) increased significantly, and were associated with a trend toward decreased
insulin sensitivity. The lipid profile worsened, as reflected in a trend toward increased
triglyceride levels and a significant increase in total cholesterol (P = 0.0129), which was largely
due to increased LDL.
Of the novel risk markers, leptin (P = 0.0215) and E-selectin (P = 0.0195) increased
significantly and adiponectin decreased significantly (P = 0.0371), representing a worsening
in these markers with treatment. Correlations between BMI changes and lab value changes
revealed only one significant relationship, for E-selection (r = 0.66, P = 0.038), indicating a
modest association between increasing E-selectin and increasing BMI during treatment.
Graham et al. Page 5














In this report, we determined that BMI as well as several other markers of CVD risk were
similar in a cohort of first episode psychotic (FEP) adults who were studied before or within
weeks of starting antipsychotic medication compared to a group of healthy individuals of
comparable age, gender, and ethnicity. The only measured difference was a higher fasting
glucose in the FEP group. However, in a subset of patients re-examined after 24 weeks of
treatment there was a statistically significant worsening in seven out of 12 laboratory risk
markers for CVD and T2DM. It is noteworthy that these changes occurred over a relatively
short period of time and in a group of young adults. It should also be noted that despite these
statistically significant changes, most of the traditional CVD risk factors remained within a
low risk range (i.e., glucose); thus, their long-term clinical significance remains uncertain. The
exception to this pattern was total cholesterol, which increased into the high (>200 mg/dl) range
during the course of treatment in the FEP subjects. Sengupta and colleagues (Sengupta et al.,
2005) studied 9 patients very early into treatment with antipsychotic medications and found
significant increase in total cholesterol and LDL-cholesterol after 3 to 4 months but no increases
in triglycerides, HDL, insulin, insulin resistance or glucose.
Previously, our group reported an increase in body fat by dual X-ray absorptiometry and an
increase in waist circumference in FEP adults treated with olanzapine for 3 months (Graham
et al., 2005). The increased leptin and decreased adiponectin observed after 6 months of
treatment in the current study are consistent with these observations. Leptin, produced
primarily in adipocytes, is well established to increase with body fat. Excessive body fat (i.e.,
obesity) is also strongly linked to diminished insulin sensitivity, which is, in turn, associated
with diminished adiponectin (Furler et al., 2006). In the present study, insulin sensitivity tended
to decrease during the treatment period in the group of FEP subjects, as well. Future studies
that prospectively evaluate changes in insulin sensitivity simultaneously with changes in
adiponectin and body composition within larger, more heterogeneous patient samples are
needed to improve our understanding of the mechanisms underlying changes in body
composition and obesity-related CVD risk in FEP subjects.
Endothelial dysfunction is a common precursor to CVD, T2DM and stroke. Elevated levels of
various cellular adhesion molecules including E-selectin and vascular cell adhesion molecule
1 (VCAM-1) are considered putative markers of endothelial dysfunction. These cellular
adhesion molecules are typically elevated in individuals at risk for T2DM, and they are elevated
further in diabetic patients who have had silent cerebral infarction (Kawamura et al. 1998). A
recent longitudinal study in T2DM patients (Stehouwer et al., 2002) indicated that endothelial
dysfunction and inflammation progress together over time, each influencing the other and
creating a vicious downward spiral. In our group of patients, E-selectin (but not VCAM-1 or
IL-6) increased over the course of treatment. Longer duration studies will be necessary to
understand the clinical significance and reproducibility of this finding, its role in the unfolding
of this complex cycle of events, and its contribution to diabetic outcomes in patients treated
with SGAs.
In the present study, the distribution of a number of the risk marker values changed significantly
between the baseline and 6 month follow-up assessments; specifically, the ranges for E-
selectin, leptin, adiponectin, insulin, glucose and cholesterol broadened. This suggests that the
study medications may have adversely affected some participants more than others.
Determining the causes of this variability is essential to understanding why some SGA-treated
patients develop CVD and T2D and others do not. With a larger sample, statistical analysis of
risk marker changes for the individual SGAs will be very important.
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There are several limitations to our study including small sample size and short follow-up
period. In this pilot study, no statistical adjustments were made for controlling error. Thus,
both our positive as well as our negative findings should be viewed judiciously, and larger
studies should be planned that will permit such important statistical control. The lack of drug
free status at baseline for all FEP subjects may be viewed as a potential limitation, but one that
is inherent (for both ethical and practical reasons) to studies with this patient population.
Additionally, since most patients and all control subjects were not hospitalized prior to their
blood draw, their fasting status was not verified. This may have occurred more often in the
patient group because of symptoms such as disorganization leading to greater difficulty in
following directions, possibly contributing to the greater glucose value at baseline for the
patient group compared to the control group. To maximize true fasting status all subjects were
given both written and oral instructions on fasting, as well as a reminder call the day before.
In summary, several key laboratory indicators of inflammation and endothelial dysfunction
worsened in this cohort of FEP patients early in their treatment (i.e., during approximately the
first 6–8 months of SGA use). This pattern of effects suggests that SGAs may confer excess
CVD and diabetes risk partly via their impact on inflammatory and vascular processes. Early
intervention to prevent these underlying pathogenic developments may be warranted.
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Percentages of healthy comparison group at baseline and first episode psychotic patient (FEP)
group at baseline and after 6 months of antipsychotic treatment that were lean (body mass index
[BMI] ≤ 24.9 kg/m2; white bar), overweight (BMI = 25 to 29.9 kg/m2; gray bar), and obese
(BMI ≥ 30 kg/m2; black bar).
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